![]() |
市场调查报告书
商品编码
1327709
多工化验市场:类型(蛋白质,核酸,细胞)技术(流式细胞技术,PCR,免疫测量)用途(研究开发,诊断产品),各终端用户-2030年前的世界预测Multiplex Assays Market by Type (Protein, Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis Product), End User - Global Forecast to 2030 |
到 2030 年,全球多工化验市场预计将达到 62.4 亿美元,2023 年至 2030 年复合年增长率为 9.0%。
该报告在广泛的二级和一级研究以及对市场情景的详细分析后,对关键行业推动因素、限制因素、挑战和机会进行了分析。该市场的成长是由于多工化验相对于单一检测的优势、多工化验在伴随诊断中的应用、慢性病和传染病患者病率的增加以及人们对早期疾病诊断重要性的认识不断提高而推动的。这是由于以下几个原因因素。然而,多工化验设备的高成本限制了市场的成长。
对高通量、自动化测试系统的需求不断增长,以及对个人化医疗的日益关注,预计将为该市场的参与者提供成长机会。然而,缺乏熟练的专业人员和交叉反应的风险是市场成长的主要挑战。
本报告基于对产品组合、区域影响力以及行业领先市场参与者多年来(2020-2023 年)采取的关键策略发展的广泛评估,提供了竞争格局。全球多工化验市场的主要公司包括 Thermo Fisher Scientific, Inc.(美国)、Bio-Rad Laboratories, Inc.(美国)、Seegene, Inc.(韩国)和 Qiagen NV(荷兰)。PerkinElmer, Inc.(美国) 、F. Hoffmann-La Roche Ltd.(瑞士)、Agilent Technologies, Inc. Ltd.(瑞士)、Agilent Technologies, Inc.(美国)、Abbott Laboratories(美国)、Siemens Healthineers AG(德国)、Illumina, Inc. (美国)、Becton, Dickinson and Company(美国)、Quanterix Corporation(美国)、DiaSorin SpA(义大利)、Merck KGaA(德国)。
(附註:SWOT分析描述了前五名公司)
Multiplex Assays Market by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Cardiovascular, Infectious, Autoimmune Diseases) Product, End User-Global Forecast to 2030
The global multiplex assays market is expected to reach $6.24 billion by 2030 at a CAGR of 9.0% from 2023 to 2030.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market is attributed to several factors, the advantages of multiplex assays over singleplex assays, the use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, and rising awareness about the importance of early disease diagnosis. However, the high costs of multiplex assay equipment restrain the growth of this market.
The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine is expected to generate growth opportunities for the players operating in this market. However, the shortage of skilled professionals and the risk of cross-reactivity are major challenges to market growth.
Among all the types studied in this report, in 2023 protein multiplex assays segment is expected to account for the largest share of the multiplex assays market. Protein multiplex assays are further segmented into bead-based assays and planar assays. In 2023, the bead-based assays segment is expected to account for the largest share of the protein multiplex assays market. Multiplex bead-based assays have become essential tools for diagnosing various diseases. These assays are used for testing allergies, cancer markers, cytokines, cardiac markers, autoimmune diseases, and endocrine diseases. Bead-based assays offer a dynamic range of analytes as they are measured using flow cytometry. They are suitable for high-throughput analysis and are much more rapid, making them the preferred alternative to planar assays.
Among all the products studied in this report, in 2023, the consumables segment is expected to account for the largest share of the multiplex assays market. The large market share of this segment is attributed to the repetitive use of kits, the growing portfolio of disease-specific kits for early diagnosis of diseases, and the increasing product approvals. The continuous advancements in reagents and kits, the development of user-friendly diagnostic kits, and the adoption of multiplex assay kits in clinical and research laboratories positively impact the demand for consumables used in multiplex assays.
Among all the technologies studied in this report, the flow cytometry segment is projected to register the highest CAGR during the forecast period. Flow cytometry is considered an important tool in clinical diagnosis and research & development. It provides a multiparametric analysis of many single cells, which can be used in multiple research areas. Additionally, market players are launching advanced flow cytometers to support growing market needs. For instance, in June 2023, Becton, Dickinson and Company (U.S.) launched a BD FACSDuet to automate sample preparation during clinical flow cytometry diagnostics.
Among all the applications studied in this report, in 2023, the research & development segment is expected to account for the largest share of the multiplex assays market. The large market share of this segment is attributed to increasing applications of multiplex assays in drug discovery, biomarker profiling, and understanding disease mechanisms. The demand for multiplex assays in research & development is increasing rapidly and is also contributing to the largest share of the segment.
Among all the end users studied in this report, the research & development segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to factors such as the increasing R&D investments by pharmaceutical & biotechnology companies, the widespread utilization of multiplex assays in drug discovery & development, and a growing emphasis on personalized medicine research. The rising spending on R&D by pharmaceutical companies is also contributing to the largest share of this segment.
An in-depth analysis of the geographical scenario of the global multiplex assays market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the multiplex assays market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's large share is attributed to the region's high R&D spending by the pharmaceutical & biotechnology companies for the development of drugs and biomarker identification, increasing prevalence of chronic diseases, rising healthcare expenditure, presence of leading market players in the region, and favorable government initiatives for research & development. According to the U.S. Congressional Budget Office, U.S. pharmaceutical R&D expenditure increased from 91.1 billion in 2020 to 102.3 billion in 2021.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years (2020-2023). The key players operating in the global multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), Qiagen N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany).
Multiplex Assays Market Assessment, by Type
Multiplex Assays Market Assessment, by Product
Multiplex Assays Market Assessment, by Technology
Note: Other technologies consist of microarray and immunohistochemistry
Multiplex Assays Market Assessment, by Application
Note: Other diseases include neurological diseases, thrombosis, and drug abuse testing.
Multiplex Assays Market Assessment, by End User
Note: Other end users consist of academic institutes & research centers, forensic labs, agriculture companies, and food & beverage companies
Multiplex Assays Market Assessment, by Geography
(Note: SWOT analysis is provided for the top 5 companies)